Early‐stage vocal cord cancer treated with hypofractionated radiotherapy to the larynx with or without concurrent chemotherapy. Issue 11 (11th August 2022)

• Record Type: Journal Article
• Authors: de Leo, Alexandra N.; Dagan, Roi; Morris, Christopher G.; Holtzman, Adam L.; Hitchcock, Kathryn E.; Bryant, Curtis M.; Amdur, Robert J.; Mendenhall, William M.
• Is Part Of: Head & neck. Volume 44:Issue 11(2022)
• Page Start: 2513
• Page End: 2521
• Publication Date: 2022-08-11
• Subjects: cancer outcomes -- chemotherapy -- head and neck -- hypofractionation -- radiation therapy; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.27165
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: We report outcomes among patients with T2 and select T3 glottic squamous cell carcinoma (SCC) treated with radiotherapy. Methods: We reviewed T2 and T3 (only paraglottic space invasion) N0 M0 glottic SCC patients treated with curative‐intent hypofractionated larynx radiotherapy, with or without concurrent systemic therapy. Results: Of 71 patients, those who received concurrent chemotherapy (23/71; 32%) had worse prognostic factors, including impaired cord mobility (70% vs. 40%, p = 0.02) and larger median gross tumor volume (3.0 vs. 1.6 cm 3, p = 0.003). Over a median follow‐up of 3.8 years, 2‐year local control among patients with impaired cord mobility appeared higher for those who received chemotherapy (88% vs. 61%, p = 0.12), but the difference was not statistically significant. Acute and late toxicity rates were not higher among patients who received chemotherapy. Conclusions: The addition of concurrent platinum‐based chemotherapy to hypofractionated larynx radiotherapy among patients with early‐stage glottic SCC with impaired cord mobility appears safe and worthy of additional investigation.